Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced plans to announce topline data from its phase 3 registrational clinical trial of ZYN002 in Fragile X syndrome in Q3 2025. The company also announced 16% year-over-year revenue growth for WAKIX® in Q2 2025, driven by strong patient adds of 400 for the quarter, continuing its trajectory toward blockbuster status in narcolepsy and a potential $1B+ market opportunity. The company continues to b
Related Questions
How does the 16% YoY revenue growth for WAKIX compare to analyst consensus estimates and competitor performance?
What are the likely regulatory pathways and timelines for FDA approval if the Phase 3 data meet its primary endpoints?
How might the Q2 2025 WAKIX revenue growth influence the company's 2025 revenue guidance revisions?
Will the company need to raise additional capital to fund commercialization of ZYN002, and what impact could that have on dilution?
Are there any outstanding clinical or safety concerns that could affect investor perception of ZYN002’s risk‑reward profile?
How will the upcoming Fragile X Phase 3 topline data impact Harmony Biosciences' stock price in the short term?
Could the data release trigger increased volatility or volume spikes that present trading opportunities?
What is the competitive landscape for Fragile X treatments and how might ZYN002’s results position HRMY against peers?
What is the projected market size for a ZYN002 therapy in Fragile X syndrome and its potential upside for HRMY?
What is the expected magnitude of revenue contribution from ZYN002 if the Phase 3 results are positive?